FdaApplication
NDA 208573
Identifiers
- fda_app_no: NDA208573
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2016-04-11 |
Revenue by product
VENCLEXTA
| Period | Revenue |
|---|---|
| Q2 2026 | $771.0M |
| Q1 2026 | $770.0M |
| Q4 2025 | $710.0M |
| Q3 2025 | $726.0M |
| Q2 2025 | $691.0M |
| Q1 2025 | $665.0M |
| Q4 2024 | $655.0M |
| Q3 2024 | $677.0M |
| Q2 2024 | $637.0M |
| Q1 2024 | $614.0M |
| Q4 2023 | $589.0M |
| Q3 2023 | $590.0M |
| Q2 2023 | $571.0M |
| Q1 2023 | $538.0M |
| Q4 2022 | $516.0M |
| Q3 2022 | $515.0M |
| Q2 2022 | $505.0M |
| Q1 2022 | $473.0M |
| Q4 2021 | $488.0M |
| Q3 2021 | $492.0M |
| Q2 2021 | $435.0M |
| Q1 2021 | $405.0M |
| Q4 2020 | $365.0M |
| Q3 2020 | $352.0M |
| Q2 2020 | $303.0M |
| Q1 2020 | $317.0M |
| Q4 2019 | $251.0M |
| Q3 2019 | $221.0M |
| Q2 2019 | $169.0M |
| Q1 2019 | $151.0M |
| Q4 2018 | $124.0M |
| Q3 2018 | $96.0M |
| Q2 2018 | $65.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VENCLEXTA | VENETOCLAX | 50MG | TABLET;ORAL |
| VENCLEXTA | VENETOCLAX | 10MG | TABLET;ORAL |
| VENCLEXTA | VENETOCLAX | 100MG | TABLET;ORAL |
3 products